TGA Peptide Safety Update: Australia Focuses on Unapproved Products
James MitchellMSc Biochemistry Current TGA Focus
As of this May 28, 2026 audit, we did not find a current, peptide-wide TGA scheduling review that resets the status of common research peptides as a group. The higher-confidence TGA story is narrower and more practical: TGA has published safety and compliance material about unapproved peptide products, online promotion, compounding responsibilities, and lawful access pathways.
What TGA Has Said About Peptides
BPC-157
TGA’s “Peptides and social media” article says BPC-157 has not been approved by TGA for human therapeutic use and is not included in the Australian Register of Therapeutic Goods. TGA also says BPC-157 is Schedule 4 and listed in Appendix D of the Poisons Standard.
That means casual consumer framing is not appropriate. Access, where lawful, depends on specific unapproved-therapeutic-good pathways and professional responsibilities.
GHK-Cu
TGA says GHK-Cu is not specifically scheduled in the Poisons Standard, but that does not mean products containing GHK-Cu are approved or safe for human use. If a product is marketed for therapeutic use, it still needs to be included in the ARTG or otherwise lawfully supplied.
Other Unapproved Peptide Products
TGA’s safety alert for importers, compounders, and suppliers gives examples of unapproved peptide products including BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295, often supplied in injectable form.
TGA highlights quality and safety risks, including uncertainty around manufacturing, sterility, mechanism, side effects, ingredients, dosage, and administration.
Practical Impact in Australia
Readers should not assume online peptide availability means Australian therapeutic approval.
Potential lawful pathways can include:
- Special Access Scheme
- Authorised Prescriber pathway
- Clinical trial access
- Personal importation where all conditions are met
- Appropriate prescription and compounding pathways where a health practitioner and pharmacy meet applicable requirements
Those pathways are fact-specific. They do not turn PeptideUnicorn into a clinic, prescriber, pharmacy, or patient-routing service.
What This Means for Australian Readers
- Verify whether the product is on the ARTG or is being supplied as an unapproved therapeutic good.
- Verify whether the practitioner, pharmacy, importer, or supplier has the correct authority.
- Treat injectable online peptide products as a higher-risk category.
- Do not rely on social-media claims or research-only labels as proof of legality or safety.
Sources
- TGA: Peptides and social media
- TGA: Responsibilities when importing, compounding and supplying unapproved peptide products
- TGA: Unapproved therapeutic goods
- TGA: Personal Importation Scheme